关于提供财务资助的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的 虚假记载、误导性陈述或者重大遗漏负连带责任。 一、财务资助背景概述 为保证公司经营发展的资金需求，提高公司整体资金使用效率，公司拟为以 下主体提供财务资助： 1、由公司控制且公司关联方参股的子公司，及此类子公司控制的公司； 2、公司及合并报表范围内子公司的参股公司； 3、公司合并报表范围内的房地产合作项目，在充分预留项目后续经营建设 所需资金的基础上，对于暂时闲置的盈余资金，各股东方可同比例调用；其中， 外部股东所调用的资金构成公司对外财务资助。 根据《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管 指引第1号——规范运作》等规定，本次财务资助事项已经公司第十届董事会第 二十二次会议审议通过，尚需提交公司股东大会审议。 证券代码：600736 股票简称：苏州高新 公告编号：2024-007 苏州新区高新技术产业股份有限公司 （一）由公司控制且公司关联方参股的子公司，及此类子公司控制的公司， 公司可控制其生产经营活动，整体风险可控。 （二）针对公司及合并报表范围内子公司的参股公司： 1、遵循同股同权原则，根据合 ...

证券代码：600736 股票简称：苏州高新 公告编号：2023-047 苏州新区高新技术产业股份有限公司 关于控股子公司竞得土地使用权的公告 公司将按相关规定办理后续事宜。 特此公告。 苏州新区高新技术产业股份有限公司 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 12 月 7 日，苏州新区高新技术产业股份有限公司（以下简称"公 司"）控股子公司苏州高新地产集团有限公司通过市场竞拍方式取得江苏省苏州 市苏地 2023-WG-91 号宗地土地使用权。本次竞拍相关事项已经公司 2022 年年度 董事会审议通过，并经公司 2022 年年度股东大会专项授权。现将竞得宗地的具 体情况公告如下： | 地块位置 | 地块编号 | 面积 | 用途 | 出让 | 容积率 | 建筑 | 起报总价 | 成交价 | 楼面单价 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | （㎡） | | 年限 | | 密度 | （万元） | （万元） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600736 股票简称：苏州高新 公告编号：2023-046 苏州新区高新技术产业股份有限公司 关于控股孙公司竞得土地使用权的公告 2023 年 11 月 1 日，苏州新区高新技术产业股份有限公司（以下简称"公 司"）控股孙公司苏州新军捷置地有限公司（以下简称"新军捷"）通过市场竞拍 方式取得江苏省苏州市苏地 2023-WG-78 号宗地土地使用权。新军捷为公司控股 子公司苏州高新地产集团有限公司（以下简称"地产集团"）与苏州科技城科新 文化旅游发展有限公司成立的合资公司，注册资本 2,000 万元人民币，地产集团 持有新军捷 70%股权。本次竞拍相关事项已经公司 2022 年年度董事会审议通过， 并经公司 2022 年年度股东大会专项授权。现将竞得宗地的具体情况公告如下： | 地块位置 | 地块编号 | 面积 | 用途 | 出让 | 容积率 | | 建筑 | 绿地 起报总价 | 成交价 | 楼面单价 | | --- | --- | --- | --- | --- | ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 855.40 million, a decrease of 28.75% compared to CNY 1,157.74 million in the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was CNY 42.08 million, an increase of 8.10% from CNY 40.13 million year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -1.92 million, a decrease of 103.61% compared to CNY 52.99 million in the same period last year[5]. - The basic and diluted earnings per share for Q3 2023 were both CNY 0.01, down 66.67% from CNY 0.03 in the same period last year[6]. - Total revenue for the first three quarters of 2023 was CNY 6,000,469,884.94, a decrease of 8.14% compared to CNY 6,530,091,378.10 in the same period of 2022[23]. - Total operating costs for the first three quarters of 2023 were CNY 6,145,183,709.25, down from CNY 6,593,393,434.59 in the previous year, reflecting a reduction of 6.79%[23]. - The company reported a total comprehensive income of CNY 417,751,051.17 for Q3 2023, compared to CNY 237,633,666.17 in Q3 2022, reflecting an increase of approximately 76%[24]. - The operating profit for Q3 2023 was CNY 399,941,382.67, down from CNY 432,402,633.31 in Q3 2022, reflecting a decrease of approximately 7.5%[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 67.97 billion, an increase of 4.71% from CNY 64.91 billion at the end of the previous year[6]. - The total assets as of the end of Q3 2023 amounted to CNY 67,966,704,492.32, an increase from CNY 64,909,101,187.17 at the end of Q3 2022, reflecting a growth of 4.73%[21]. - Total liabilities as of Q3 2023 were CNY 50,844,557,776.77, compared to CNY 48,212,729,836.54 in the same period of 2022, indicating an increase of 5.42%[21]. - The company's total equity as of Q3 2023 was CNY 17,122,146,715.55, up from CNY 16,696,371,350.63 in Q3 2022, showing an increase of 2.55%[21]. - The total liabilities reached ¥25,634,523,583.54, up from ¥22,650,453,426.05, indicating an increase of around 12.9%[32]. - The company's equity decreased to ¥6,503,048,091.02 from ¥6,998,960,448.38, a decline of approximately 7.1%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY -425.98 million, indicating a significant cash outflow[6]. - The net cash flow from operating activities for the first three quarters of 2023 was -CNY 425,976,436.67, compared to -CNY 3,805,116,038.09 in the same period of 2022, showing an improvement in cash flow[26]. - The cash inflow from investment activities for the first three quarters of 2023 was CNY 2,926,246,574.61, down from CNY 3,593,334,658.78 in the same period of 2022, a decrease of about 18.6%[28]. - The net cash flow from financing activities for Q3 2023 was CNY 3,570,553,077.87, compared to CNY 1,476,150,874.83 in Q3 2022, indicating a significant increase[28]. - The company’s cash inflow from financing activities in Q3 2023 was ¥9,629,080,000.00, a decrease of 34.3% from ¥14,642,470,000.00 in Q3 2022[37]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 58.543 million[13]. - The largest shareholder, Suzhou High-tech Group Co., Ltd., holds 504,194,894 shares, accounting for 43.79% of total shares[14]. Investments and Development - The company plans to continue focusing on the development of new products and technologies, as well as market expansion strategies[11]. - The company invested 20 million RMB in Changchuan Technology's private placement and 4.9 million RMB in Dongfang Tantalum's private placement during the reporting period[16]. - The medical device industrial park attracted 70 new enterprises, including leading companies in niche markets[15]. - The company’s investment in the medical device sector continues to yield results, with several portfolio companies preparing for IPOs[16]. Visitor Statistics - The company’s tourism parks received over 3.74 million visitors, a year-on-year increase of 147%[17].

根据《上海证券交易所上市公司自律监管指引第3号——行业信息披露（第 一号——房地产）》（上证发〔2022〕4号）的要求，公司现将2023年前三季度 房地产业务主要经营数据披露如下： 一、新增房地产储备及开工面积、竣工面积 2023年1-9月，公司无新增商品房土地储备；新增商品房开工面积26.50万平 方米，新增竣工面积12.58万平方米。 二、签约面积、签约金额及其同比变化情况 证券代码：600736 股票简称：苏州高新 公告编号：2023-045 苏州新区高新技术产业股份有限公司 关于 2023 年前三季度房地产业务主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 以上统计数据未经审计，最终以定期报告数据披露为准。 特此公告。 苏州新区高新技术产业股份有限公司 董事会 2023 年 10 月 28 日 报告期内，公司合同销售面积13.51万平方米，同比减少24.12%；权益合同 销售面积8.27万平方米，同比减少5.87%。 报告期内，公司合同销售金额30.34亿元，同比减少35.21%；权益合同销售 金额 ...

关于控股孙公司竞得土地使用权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 10 月 18 日，苏州新区高新技术产业股份有限公司（以下简称"公 司"）控股孙公司苏州新军捷置地有限公司（以下简称"新军捷"）通过市场竞拍 方式取得江苏省苏州市苏地 2023-WG-62 号宗地土地使用权。新军捷为公司控股 子公司苏州高新地产集团有限公司（以下简称"地产集团"）与苏州科技城科新 文化旅游发展有限公司成立的合资公司，注册资本 2,000 万元人民币，地产集团 持有新军捷 70%股权。本次竞拍相关事项已经公司 2022 年年度董事会审议通过， 并经公司 2022 年年度股东大会专项授权。现将竞得宗地的具体情况公告如下： 证券代码：600736 股票简称：苏州高新 公告编号：2023-044 苏州新区高新技术产业股份有限公司 特此公告。 苏州新区高新技术产业股份有限公司 董事会 2023 年 10 月 19 日 | 地块位置 | 地块编号 | 面积 | 用途 | 出让 | 容积率 | 建筑 | 绿地 | 起报总价 | ...

证券代码：600736 股票简称：苏州高新 公告编号：2023-043 苏州新区高新技术产业股份有限公司 关于旗下基金投资夏尔巴三期股权基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州新区高新技术产业股份有限公司（以下简称"公司"）旗下基金苏州新 苏新兴产业投资合伙企业（有限合伙）（以下简称"新苏新兴产业基金"）拟作 为有限合伙人投资夏尔巴三期股权投资合伙企业（有限合伙）（以下简称"夏尔 巴三期股权基金"或"标的基金"）。 根据《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》 的规定，现将有关事项公告如下： 一、对外投资概述 （一）基本情况 3、基金管理人简称：夏尔巴股权投资管理有限公司（以下简称"夏尔巴投 资"），成立于2018年3月22日，法定代表人为欧阳翔宇，已在中国基金业协会 登记为私募基金管理人，管理人登记编号P1068644，专注于医疗健康行业投资。 1 夏尔巴投资目前在管资产规模超过人民币30亿元，多次获得清科、投中网、36氪、 动脉网等业内各项评比奖项，具有较强的投资管理能力及 ...

2023年半年度网上业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 重要内容提示： 一、说明会类型 证券代码：600736 股票简称：苏州高新 公告编号：2023-042 苏州新区高新技术产业股份有限公司 苏州新区高新技术产业股份有限公司（以下简称"公司"）已于2023年8月 30日在《中国证券报》、《上海证券报》及上海证券交易所网站（www.sse.com.cn） 披露公司2023年半年度报告。为让广大投资者更全面深入地了解公司经营业绩、 战略转型、产业布局等具体情况，公司决定以网络互动方式召开2023年半年度业 绩说明会。 二、说明会召开时间、地点 召开时间：2023年9月21日（周四）15:00-16:00。 召开地点："苏州高新投资者关系"小程序。 召开方式：微信小程序网络互动。 三、公司出席说明会的人员 公司副董事长、总经理沈明先生，独立董事周中胜先生，副总经理、董事会 秘书宋才俊先生，总经理助理、财务总监蔡金春先生。 四、投资者参与方式 1、投资者可在2023年9月21日前通过本公告后附的电话、传真或者电子邮件 方式 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 5,145,068,772.62, a decrease of 3.46% compared to the same period last year[22]. - Net profit attributable to shareholders of the listed company reached CNY 230,802,821.52, an increase of 48.21% year-on-year[22]. - The net profit after deducting non-recurring gains and losses was CNY 144,532,176.86, reflecting an increase of 84.09% compared to the previous year[22]. - Basic earnings per share for the reporting period (1-6 months) increased to 0.15 CNY, up 7.14% from the same period last year[23]. - Diluted earnings per share for the reporting period also rose to 0.15 CNY, reflecting a 7.14% increase year-over-year[23]. - The weighted average return on equity increased to 2.41%, up by 0.34 percentage points compared to the previous year[23]. - The company reported a net profit of 26.4058 million yuan from financing leasing, with revenue reaching 82.5847 million yuan[56]. - The company’s investment income increased by 75.90% to 392.3686 million yuan, attributed to higher returns from joint venture investments[63]. - The company reported a net profit of -39,209,166 RMB for the current period, indicating a significant loss compared to previous periods[172]. Assets and Liabilities - The total assets of the company as of June 30, 2023, were CNY 65,941,225,864.89, representing a 1.59% increase from the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were CNY 7,422,061,984.96, up 2.77% from the previous year[22]. - The company's total liabilities increased to CNY 25,095,628,226.67, up from CNY 22,650,453,426.05, representing a growth of 10.79%[144]. - Total liabilities amounted to ¥48,854,724,457.11, up from ¥48,212,729,836.54, showing a growth of approximately 1.33%[141]. - The company's total liabilities at the end of the reporting period were 10,475,103,000 RMB[174]. Cash Flow - The company reported a net cash flow from operating activities of CNY -417,151,412.26, indicating a significant change from the previous year[22]. - Cash inflows from operating activities amounted to CNY 5,068,654,000.14, a decrease from CNY 5,581,423,652.80 in the first half of 2022, showing a decline of about 9%[153]. - Cash outflows from operating activities totaled CNY 5,485,805,412.40, down from CNY 10,372,729,228.17 in the previous year, indicating a reduction of approximately 47%[153]. - The net cash flow from investing activities was negative CNY 623,775,367.31, compared to a positive CNY 581,117,144.75 in the same period of 2022[154]. - Cash flow from financing activities generated a net inflow of CNY 2,278,616,511.56, down from CNY 3,080,291,192.70 in the first half of 2022, representing a decrease of about 26%[154]. Investment and Development - The company has invested a total of 2.947 billion yuan in its existing investment projects, with a continuous growth in industrial investment scale[41]. - The company established a new fund with a scale of CNY 500 million targeting emerging industries, including medical devices and renewable energy[55]. - The company is focusing on innovation-driven development in the medical device sector, which is expected to be a key growth driver in the coming years[30]. - The company is actively promoting the construction of high-standard innovation carriers, with the fourth phase of the industrial park expected to be completed in the second half of the year[49]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[152]. Environmental Responsibility - The company is committed to environmental responsibility, with specific wastewater discharge data provided, including COD levels at various treatment plants[97][98]. - The average COD discharge concentration at the Shishan Water Quality Treatment Plant was reported at 14.2 mg/L, with a total annual discharge of 204.72 tons[97]. - The company has received environmental impact assessment approvals for all water purification plant construction and upgrades from the Suzhou Environmental Protection Bureau[102]. - Emergency response plans for environmental incidents have been signed and submitted to the Suzhou High-tech Zone Environmental Supervision Team[103]. - The company has completed the self-monitoring plans required for key monitoring enterprises in Jiangsu Province[104]. Market and Industry Trends - The medical device market in China reached a scale of 1.3 trillion CNY in 2022, accounting for approximately 27.5% of the global market[30]. - The average annual compound growth rate of the medical device industry in China exceeded 12% over the past five years[30]. - In 2022, the approval of innovative medical devices by the National Medical Products Administration increased by 57%, with 55 new products approved[31]. - The government aims for non-fossil energy consumption to reach around 20% by 2025, driving growth in the green low-carbon industry[32]. - The company is facing macroeconomic risks due to the real estate market entering an adjustment period, with a focus on optimizing policies and enhancing non-real estate business to improve risk resilience[88]. Corporate Governance - The report has not been audited, but the management team guarantees its accuracy and completeness[7]. - The company has experienced changes in its board of directors, with the chairman of the supervisory board and a supervisor resigning[95]. - The financial statements were approved by the board of directors on August 28, 2023[189]. - The company has not reported any overdue bonds or related risks during the reporting period[128]. - The company has not proposed any profit distribution or capital reserve increase for the first half of 2023, indicating a focus on retaining earnings[95].

房地产估价报告 估价报告编号:天地恒安(2023)估字第15012号 估价项目名称:苏州新港建设集团有限公司所属的位于苏州高 新区金山路66-1号101室的房地产市场价值评 估 估价委托人:苏州高新区狮山商务创新区管理办公室 房地产估价机构:江苏天地恒安房地产土地资产评估有限公司 注册房地产估价师:张文奎(注册号 3220180058) 焘(注册号 3220190048) 场 估价作业期:2023年04月07日至2023年07月10日 估价报告出具日期:2023年07月10日 报告防伪查询电话:0512-68326301 联系人:张艳 罗勋荣 江苏天地恒安房地产土地资产评估有限公司 房地产估价报告 贵方为收购企业之房地产,委托本房地产估价机构对苏州新港建设 集团有限公司所有的位于苏州高新区金山路 66-1 号 101 室的非居住房地 产进行房地产价值评估,估价对象的《房屋所有权证》证号为苏房权证 新区字第 00167646号,登记房屋建筑面积合计为 5077.26M2,《国有土 地使用权证》证号为苏新国用(2011)第 010825 号,登记土地面积为 2297.50M²,土地使用权为出让商务金融用地。本次估 ...